#United States #BioLife Solutions #Bothell #cell processing #CGT Market

BioLife Solutions Reports First Quarter 2025 Financial Results

BioLife Solutions, Inc., a prominent player in the cell and gene therapy market, has announced its financial results for the first quarter of 2025, marking a strong start to the year with impressive growth figures. The company's cell processing revenue reached $21.6 million, reflecting a remarkable 33% increase over the same quarter in 2024. This growth was primarily driven by robust sales in their biopreservation media product line, which has become a critical component for commercial therapy customers, now accounting for approximately 40% of total revenue in this segment.

Roderick de Greef, the Chairman and CEO, expressed confidence in the company's trajectory, stating that the growth has highlighted the resilience of BioLife's model. He believes their streamlined organization has unlocked further operational efficiencies, which is evident in the significant expansion of the adjusted EBITDA margin—recording $5.7 million, or 24% of revenue.

Financial Performance Overview

The total revenue for the quarter was $23.9 million—a notable rise of 30% from $18.4 million in Q1 2024. Specifically, the cell processing platform revenue saw a growth of $5.4 million sequentially, indicating sustained strength in this sector. The evo and Thaw platform revenue experienced a slight dip, settling at $2.3 million but still showing stability relative to the previous quarter.

In terms of profitability, BioLife reported a gross margin of 63% (GAAP) for Q1 2025, consistent with the previous year. The adjusted gross margin climbed to 66%. The net loss from continuing operations was reduced to $0.4 million compared to $3.2 million one year prior, demonstrating improved operational efficiency.

Business Highlights

The first quarter was marked by several key accomplishments, including:

• - Processing of 13 new U.S. FDA Master File cross references for their biopreservation media, increasing the cumulative total to 782.
• - The incorporation of their biopreservation media in 17 unique commercial cell and gene therapies, with further expectations for approvals of up to 10 additional products and geographical expansions in the upcoming year.
• - The successful acquisition of PanTHERA CryoSolutions on April 4, which enhances BioLife’s technological capabilities in cryopreservation, a strategic move to solidify their leadership in the biopreservation space.

Looking Ahead

BioLife Solutions has re-affirmed its revenue guidance for 2025, expecting a range of $95.5 million to $99.0 million—an anticipated growth of 16% to 20% compared to the previous year.

With a solid cash position of $107.6 million as of March 31, BioLife is poised to continue investing in innovative solutions and expanding its market presence through both organic growth and strategic acquisitions. As the cell and gene therapy market continues to evolve, BioLife remains committed to driving advancements that deliver long-term value to its shareholders.

Management’s optimistic outlook for the remainder of 2025 indicates their focus on enhancing operational capabilities, exploring new market opportunities, and maintaining a healthy balance sheet. With dynamic operational strategies in place, BioLife Solutions appears on track to achieve its ambitious growth plans for the year and beyond.

For more information on the financial results or to participate in the conference call with management, interested parties can visit BioLife's Investor Relations page or dial in at the scheduled time for live updates on the company's performance and future strategies.